SCHEMBL2020191

SCHEMBL2020191

Cc1cccc(C)c1-c1nnc(N(C)Cc2cccc(C(F)(F)F)c2)c2ccccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 3/20 0.44
OPRM1 P35372 1/20 0.41
OPRL1 P41146 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
HTR2B P41595 1/20 0.39
TAAR1 Q96RJ0 1/20 0.38
APP P05067 2/20 0.38
IDO1 P14902 2/20 0.37
CETP P11597 2/20 0.37
NR3C1 P04150 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
GABRA1 P14867 1/20 0.36
GABRG2 P18507 1/20 0.36
GABRB3 P28472 1/20 0.36
GABRA5 P31644 1/20 0.36
SCN8A Q9UQD0 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2020985 0.88 CSF1R (0.43) CSF1RMEN1KMT2AAPPNR3C1
SCHEMBL2022779 0.81 SCN8A (0.35) CSF1RIDO1NR3C1ALDH1A1SCN8A
SCHEMBL2021464 0.81 SMN1; SMN2 (0.49) CSF1RMEN1KMT2ATAAR1IDO1
SCHEMBL2016765 0.77 GABRA1 (0.46) CSF1RKMT2AALDH1A1HPGDGABRA1
SCHEMBL2016512 0.76 GBA1 (0.48) ALDH1A1HPGD
SCHEMBL2019715 0.74 ALDH1A1 (0.48) CSF1RMEN1KMT2AALDH1A1HPGD
SCHEMBL2019830 0.72 CSF1R (0.40) CSF1RMEN1KMT2AGABRA1GABRG2
SCHEMBL2017558 0.69 CSF1R (0.43) CSF1RMEN1KMT2AALDH1A1GABRA1
SCHEMBL2019153 0.69 EGFR (0.41) MEN1KMT2AHTR2ATAAR1NR3C1
SCHEMBL4243270 0.68 HTR2A (0.56) OPRM1OPRL1MEN1KMT2AHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338591-B2 3-aryl-5,6-disubstituted pyridazines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-12-25 US claimed
US-8338591-B2 3-aryl-5,6-disubstituted pyridazines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-12-25 US disclosed
US-20110160187-A1 3-aryl-5,6-disubstituted pyridazines NEUROGEN CORPORATION (US) 2011-06-30 US disclosed
US-20110160187-A1 3-aryl-5,6-disubstituted pyridazines NEUROGEN CORPORATION (US) 2011-06-30 US disclosed
US-20110160187-A1 3-aryl-5,6-disubstituted pyridazines NEUROGEN CORPORATION (US) 2011-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160187-A1 3-aryl-5,6-disubstituted pyridazines MMP25, MMP9, MMP3 CSF1R 1219/4885OPRM1 3858/4885OPRL1 3030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.